Antimicrobial peptides and proteins, exercise and innate mucosal immunity

FEMS Immunology and Medical Microbiology

Volumn 48, Issue 3, 2006, Pages 293-304

  West, Nicholas P ^a,b   Pyne, David B ^b,c   Renshaw, Gillian ^a   Cripps, Allan W ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b AUSTRALIAN INSTITUTE OF SPORT   (Australia)

^c The Australian National University   (Australia)

Author keywords

Antimicrobial peptides and proteins; Exercise; Innate immunity; Lactoferrin; Lysozyme; Upper respiratory tract infection

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIMICROBIAL ACTIVITY; DISEASE PREDISPOSITION; DOSE RESPONSE; EXERCISE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MOLECULAR RECOGNITION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SURFACE PROPERTY;

ANIMALS; EXERCISE; EXERTION; HUMANS; IMMUNITY, NATURAL; INFECTION; MUCOUS MEMBRANE; PHYSICAL CONDITIONING, ANIMAL; STRESS; STRESS, PSYCHOLOGICAL;

EID: 33750932567     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00132.x     Document Type: Short Survey

References (72)

1. Arditi M, Zhou J, Dorio R, Rong GW, Goyert SM & Kim KS (1993) Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun 61: 3149-3156.
2. Arnold D, Di Biase AM, Marchetti M, Pietrantoni A, Valenti P, Seganti L & Superti F (2002) Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res 53: 153-158.
3. Arnt L, Rennie JR, Linser S, Willumeit R & Tew GN (2006) Membrane activity of biomimetic facially amphiphilic antibiotics. J Phys Chem B Condens Matter Mater Surf Interfaces Biophys 110: 3527-3532.
4. Barrett B, Locken K, Maberry R, Schwamman J, Brown R, Bobula J & Stauffacher EA (2002) The Wisconsin Upper Respiratory Symptom Survey (WURSS): a new research instrument for assessing the common cold. J Fam Pract 51: 265-273.
5. Baveye S, Elass E, Fernig DG, Blanquart C, Mazurier J & Legrand D (2000) Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 68: 6519-6525.
6. Bennett-Guerrero E, Barclay GR, Weng PL, Bodian CA, Feierman DE, Vela-Cantos F & Mythen MG (2001) Endotoxin-neutralizing capacity of serum from cardiac surgical patients. J Cardiothorac Vasc Anesth 15: 451-454.
7. Bowdish DM, Davidson DJ & Hancock RE (2005) A reevaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci 6: 35-51.
8. Brandenburg K, Jurgens G, Muller M, Fukuoka S & Koch MH (2001) Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 382: 1215-1225.
9. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML & Krieg AM (2001) Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol 167: 2921-2928.
10. Clarke NM & May JT (2000) Effect of antimicrobial factors in human milk on rhinoviruses and milk-borne cytomegalovirus in vitro. J Med Microbiol 49: 719-723.
11. Cole AM, Dewan P & Ganz T (1999) Innate antimicrobial activity of nasal secretions. Infect Immun 67: 3267-3275.
12. Daele J & Zicot AF (2000) Humoral immunodeficiency in recurrent upper respiratory tract infections. Some basic, clinical and therapeutic features. Acta Oto-Rhino-Laryngol Belg 54: 373-390.
13. De Y, Chen Q, Schmidt AP et al. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192: 1069-1074.
14. Devine DA & Hancock RE (2002) Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Des 8: 703-714.
15. Dixon RE (1985) Economic costs of respiratory tract infections in the United States. Am J Med 78: 45-51.
16. Dorschner RA, Pestonjamasp VK, Tamakuwala S et al. (2001) Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117: 91-97.
17. Dubin RF, Robinson SK & Widdicombe JH (2004) Secretion of lactoferrin and lysozyme by cultures of human airway epithelium. Am J Physiol Lung Cell Mol Physiol 286: L750-L755.
18. Duits LA, Nibbering PH, van Strijen E, Vos JB, Mannesse-Lazeroms SP, van Sterkenburg MA & Hiemstra PS (2003) Rhinovirus increases human beta-defensin-2 and -3 mRNA expression in cultured bronchial epithelial cells. FEMS Immunol Med Microbiol 38: 59-64.
19. Elsbach P (2003) What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? J Clin Invest 111: 1643-1645.
20. Ginsburg I (2004) Bactericidal cationic peptides can also function as bacteriolysis-inducing agents mimicking beta-lactam antibiotics?; it is enigmatic why this concept is consistently disregarded. Med Hypotheses 62: 367-374.
21. Glaser R, Friedman SB, Smyth J et al. (1999) The differential impact of training stress and final examination stress on herpesvirus latency at the United States military academy at west point. Brain Behav Immun 13: 240-251.
22. Gleeson M (2000) Mucosal immune responses and risk of respiratory illness in elite athletes. Exerc Immunol Rev 6: 5-42.
23. Gleeson M, Hall ST, McDonald WA, Flanagan AJ & Clancy RL (1999a) Salivary IgA subclasses and infection risk in elite swimmers. Immunol Cell Biol 77: 351-355.
24. Gleeson M, McDonald WA, Pyne DB, Cripps AW, Francis JL, Fricker PA & Clancy RL (1999b) Salivary IgA levels and infection risk in elite swimmers. Med Sci Sports Exerc 31: 67-73.
25. Gleeson M, Pyne DB & Callister R (2003) Exercise effects on mucosal immunity and risk of upper respiratory illness. Int J Sports Med 4: 1-14.
26. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ & McDermott AM (2005) Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 30: 385-394.
27. Grover M, Giouzeppos O, Schnagl RD & May JT (1997) Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acta Paediatr 86: 315-316.
28. Gwaltney JM (2002) Clinical significance and pathogenesis of viral respiratory infections. Am J Med 112: 13S-18S.
29. Hancock RE (2001) Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1: 156-164.
30. Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH & Meijer DK (1995) Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172: 380-388.
31. Hashem M & Hall CB (2003) Respiratory syncytial virus in healthy adults: the cost of a cold. J Clin Virol 27: 14-21.
32. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA & Mattsby-Baltzer I (2002) Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220: 83-95.
33. Helmerhorst EJ, Breeuwer P, van't Hof W et al. (1999) The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem 274: 7286-7291.
34. Ibrahim HR, Inazaki D, Abdou A, Aoki T & Kim M (2005) Processing of lysozyme at distinct loops by pepsin: a novel action for generating multiple antimicrobial peptide motifs in the newborn stomach. Biochim Biophys Acta 1726: 102-114.
35. Inoue H, Sakai M, Kaida Y & Kaibara K (2004) Blood lactoferrin release induced by running exercise in normal volunteers: antibacterial activity. Clin Chim Acta 341: 165-172.
36. Kanyshkova TG, Babina SE, Semenov DV et al. (2003) Multiple enzymic activities of human milk lactoferrin. Eur J Biochem 270: 3353-3361.
37. Kirkland TN, Finley F, Leturcq D, Moriarty A, Lee JD, Ulevitch RJ & Tobias PS (1993) Analysis of lipopolysaccharide binding by CD14. J Biol Chem 268: 24818-24823.
38. Koczulla R, von Degenfeld G, Kupatt C et al. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111: 1665-1672.
39. Koh D, Yong Y, Ng V & Chia SE (2002) Stress, mucosal immunity, upper respiratory tract infections, and sickness absence. J Occup Environ Med 44: 987-988.
40. Le Roy D, Di Padova F, Adachi Y, Glauser MP, Calandra T & Heumann D (2001) Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria. J Immunol 167: 2759-2765.
41. Legrand D, Elass E, Pierce A & Mazurier J (2004) Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals 17: 225-229.
42. Leitch EC & Willcox MD (1999) Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J Med Microbiol 48: 867-871.
43. Lopez-Garcia B, Lee PH, Yamasaki K & Gallo RL (2005) Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125: 108-115.
44. Matsuzaki K (1999) Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1462: 1-10.
45. McPhee JB & Hancock RE (2005) Function and therapeutic potential of host defence peptides. J Pept Sci 11: 677-687.
46. Muns G (1994) Effect of long-distance running on polymorphonuclear neutrophil phagocytic function of the upper airways. Int J Sports Med 15: 96-99.
47. Muns G, Singer P, Wolf F & Rubinstein I (1995) Impaired nasal mucociliary clearance in long-distance runners. Int J Sports Med 16: 209-213.
48. Murakami M, Ohtake T, Dorschner RA & Gallo RL (2002) Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 81: 845-850.
49. Nieman DC, Henson DA, Sampson CS et al. (1995) The acute immune response to exhaustive resistance exercise. Int J Sports Med 16: 322-328.
50. Nizet V, Ohtake T, Lauth X et al. (2001) Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414: 454-457.
51. Ong PY, Ohtake T, Brandt C et al. (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347: 1151-1160.
52. Peake J, Wilson G, Hordern M et al. (2004) Changes in neutrophil surface receptor expression, degranulation, and respiratory burst activity after moderate- and high-intensity exercise. J Appl Physiol 97: 612-618.
53. Pyne DB (1994) Regulation of neutrophil function during exercise. Sports Med 17: 245-258.
54. Pyne DB & Gleeson M (1998) Effects of intensive exercise training on immunity in athletes. Int J Sports Med S183-S191; discussion S191-S194.
55. Pyne DB, McDonald WA, Gleeson M, Flanagan A, Clancy RL & Fricker PA (2001) Mucosal immunity, respiratory illness, and competitive performance in elite swimmers. Med Sci Sports Exerc 33: 348-353.
56. Quinones-Mateu ME, Lederman MM, Feng Z et al. (2003) Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 17: F39-F48.
57. Reddy KV, Yedery RD & Aranha C (2004) Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 24: 536-547.
58. Samuelsen O, Haukland HH, Ulvatne H & Vorland LH (2004) Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol 41: 141-148.
59. Scott MG, Vreugdenhil AC, Buurman WA, Hancock RE & Gold MR (2000) Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 164: 549-553.
60. Seydel U, Hawkins L, Schromm AB, Heine H, Scheel O, Koch MH & Brandenburg K (2003) The generalized endotoxic principle. Eur J Immunol 33: 1586-1592.
61. Shinoda I, Takase M, Fukuwatari Y, Shimamura S, Koller M & Konig W (1996) Effects of lactoferrin and lactoferricin on the release of interleukin 8 from human polymorphonuclear leukocytes. Biosci Biotechnol Biochem 60: 521-523.
62. Singh PK, Tack BF, McCray PB Jr & Welsh MJ (2000) Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 279: L799-L805.
63. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T & Borregaard N (2003) Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 170: 5583-5589.
64. Spence L, Nissen M, Sloots T et al. (2004) Identifying the aetiology of upper respiratory illness in elite and recreational athletes. Proceedings of the Australian Conference of Science and Medicine in Sport, 6-9 October 2004, Alice Springs, Australia, Abstract 80.
65. Tjabringa GS, Vos JB, Olthuis D et al. (2005) Host defense effector molecules in mucosal secretions. FEMS Immunol Med Microbiol 45: 151-158.
66. Tomasi TB, Trudeau FB, Czerwinski D & Erredge S (1982) Immune parameters in athletes before and after strenuous exercise. J Clin Immunol 2: 173-178.
67. Toy LS & Mayer L (1996) Basic and clinical overview of the mucosal immune system. Semin Gastrointest Dis 7: 2-11.
68. Travis SM, Conway BA, Zabner J et al. (1999) Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 20: 872-879.
69. Wakabayashi H, Takase M & Tomita M (2003) Lactoferricin derived from milk protein lactoferrin. Curr Pharm Des 9: 1277-1287.
70. Yang D, Chertov O, Bykovskaia SN et al. (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286: 525-528.
71. Yang D, Chertov O & Oppenheim JJ (2001) The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci 58: 978-989.
72. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75: 39-48.